{
    "root": "d76dcbf4-6839-4396-9eb5-b0e6edadbed9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "voriconazole",
    "value": "20250401",
    "ingredients": [
        {
            "name": "VORICONAZOLE",
            "code": "JFU09I87TR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10023"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9661"
        }
    ],
    "indications": {
        "text": "voriconazole tablets azole antifungal indicated treatment adults pediatric patients 2 years age older : \u2022 invasive aspergillosis ( 1.1 ) \u2022 candidemia non-neutropenics deep tissue candida infections ( 1.2 ) \u2022 esophageal candidiasis ( 1.3 ) \u2022 serious fungal infections caused scedosporium apiospermum fusarium species including fusarium solani , patients intolerant , refractory , therapy ( 1.4 )",
        "doid_entities": [
            {
                "text": "invasive aspergillosis (DOID:0050073)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050073"
            },
            {
                "text": "aspergillosis (DOID:13564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13564"
            },
            {
                "text": "esophageal candidiasis (DOID:13146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13146"
            },
            {
                "text": "candidiasis (DOID:1508)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1508"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 adults ( 2.3 ) infection loading dose maintenance dose intravenous infusion intravenous infusion oral tablets invasive aspergillosis 6 mg/kg every 12 hours first 24 hours 4 mg/kg every 12 hours 200 mg every 12 hours candidemia nonneutropenics deep tissue candida infections 3 4 mg/kg every 12 hours 200 mg every 12 hours scedosporiosis fusariosis 4 mg/kg every 12 hours 200 mg every 12 hours esophageal candidiasis evaluated evaluated 200 mg every 12 hours \u2022 adult patients weighing less 40 kg : oral maintenance dose 100 mg 150 mg every 12 hours \u2022 hepatic impairment : half maintenance dose adult patients mild moderate hepatic impairment ( child-pugh class b ) ( 2.5 ) \u2022 renal impairment : avoid intravenous adult patients moderate severe renal impairment ( creatinine clearance < 50 ml/min ) ( 2.6 ) \u2022 pediatric patients 2 years age older ( 2.4 ) \u2022 pediatric patients 2 less 12 years age 12 14 years age weighing less 50 kg table . infection loading dose maintenance dose intravenous infusion intravenous infusion oral tablets invasive aspergillosis 9 mg/kg every 12 hours first 24 hours 8 mg/kg every 12 hours first 24 hours 9 mg/kg every 12 hours ( maximum dose 350 mg every 12 hours ) candidemia nonneutropenics deep tissue candida infections scedosporiosis fusariosis esophageal candidiasis evaluated 4 mg/kg every 12 hours 9 mg/kg every 12 hours ( maximum dose 350 mg every 12 hours ) \u2022 pediatric patients aged 12 14 years weighing greater equal 50 kg aged 15 years older regardless body weight adult . ( 2.4 ) \u2022 adjustment voriconazole pediatric patients renal hepatic impairment established . ( 2.5 , 2.6 )",
        "doid_entities": [
            {
                "text": "invasive aspergillosis (DOID:0050073)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050073"
            },
            {
                "text": "aspergillosis (DOID:13564)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13564"
            },
            {
                "text": "fusariosis (DOID:0050289)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050289"
            },
            {
                "text": "esophageal candidiasis (DOID:13146)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13146"
            },
            {
                "text": "candidiasis (DOID:1508)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1508"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "invasive aspergillosis 6",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_1163"
            },
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "invasive aspergillosis 9",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_1163"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "\u25cf voriconazole tablets contraindicated patients known hypersensitivity voriconazole excipients . information regarding cross-sensitivity voriconazole azole antifungal agents . caution used prescribing voriconazole patients hypersensitivity azoles . \u25cf coadministration pimozide , quinidine ivabradine voriconazole contraindicated increased plasma concentrations drugs lead qt prolongation rare occurrences torsade de pointes [ ( 7 ) ] . \u25cf coadministration voriconazole sirolimus contraindicated voriconazole significantly increases sirolimus concentrations [ ( 7 ) pharmacology ( 12.3 ) ] . \u25cf coadministration voriconazole rifampin , carbamazepine , long-acting barbiturates st. john \u2019 wort contraindicated drugs likely decrease plasma voriconazole concentrations significantly [ ( 7 ) pharmacology ( 12.3 ) ] . \u25cf coadministration standard doses voriconazole efavirenz doses 400 mg every 24 hours higher contraindicated , efavirenz significantly decreases plasma voriconazole concentrations healthy subjects doses . voriconazole also significantly increases efavirenz plasma concentrations [ ( 7 ) pharmacology ( 12.3 ) ] . \u25cf coadministration voriconazole high-dose ritonavir ( 400 mg every 12 hours ) contraindicated ritonavir ( 400 mg every 12 hours ) significantly decreases plasma voriconazole concentrations . coadministration voriconazole low-dose ritonavir ( 100 mg every 12 hours ) avoided , unless assessment benefit/risk patient justifies voriconazole [ ( 7 ) pharmacology ( 12.3 ) ] . \u25cf coadministration voriconazole rifabutin contraindicated since voriconazole significantly increases rifabutin plasma concentrations rifabutin also significantly decreases voriconazole plasma concentrations [ ( 7 ) pharmacology ( 12.3 ) ] . \u25cf coadministration voriconazole ergot alkaloids ( ergotamine dihydroergotamine ) contraindicated voriconazole may increase plasma concentration ergot alkaloids , may lead ergotism [ ( 7 ) ] . \u25cf coadministration voriconazole naloxegol contraindicated voriconazole may increase plasma concentrations naloxegol may precipitate opioid withdrawal symptoms [ ( 7 ) ] . \u25cf coadministration voriconazole tolvaptan contraindicated voriconazole may increase tolvaptan plasma concen trations increase risk [ ( 7 ) ] . \u25cf coadministration voriconazole venetoclax initiation ramp-up phase contraindicated patients chronic lymphocytic leukemia ( cll ) small lymphocytic lymphoma ( sll ) due potential increased risk tumor lysis syndrome [ ( 7 ) ] . \u25cf coadministration voriconazole lurasidone contraindicated since may result significant increases lurasidone exposure potential serious [ ( 7 ) ] \u25cf coadministration voriconazole finerenone contraindicated since may result significant increases finerenone exposure potential serious [ ( 7 ) ] .",
    "indications_original": "Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients 2 years of age and older with: \u2022 Invasive aspergillosis ( 1.1 ) \u2022 Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) \u2022 Esophageal candidiasis ( 1.3 ) \u2022 Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )",
    "contraindications_original": "\u2022 Dosage in Adults ( 2.3 ) Infection Loading Dose Maintenance Dose Intravenous infusion Intravenous infusion Oral tablets Invasive Aspergillosis 6 mg/kg every 12 hours for the first 24 hours 4 mg/kg every 12 hours 200 mg every 12 hours Candidemia in nonneutropenics and other deep tissue Candida infections 3 to 4 mg/kg every 12 hours 200 mg every 12 hours Scedosporiosis and Fusariosis 4 mg/kg every 12 hours 200 mg every 12 hours Esophageal Candidiasis Not Evaluated Not Evaluated 200 mg every 12 hours \u2022 Adult patients weighing less than 40 kg: oral maintenance dose 100 mg or 150 mg every 12 hours \u2022 Hepatic Impairment : Use half the maintenance dose in adult patients with mild to moderate hepatic impairment (Child-Pugh Class A and B) ( 2.5 ) \u2022 Renal Impairment : Avoid intravenous administration in adult patients with moderate to severe renal impairment (creatinine clearance <50 mL/min) ( 2.6 ) \u2022 Dosage in Pediatric Patients 2 years of age and older ( 2.4 ) \u2022 For pediatric patients 2 to less than 12 years of age and 12 to 14 years of age weighing less than 50 kg see Table below. Infection Loading Dose Maintenance Dose Intravenous infusion Intravenous infusion Oral tablets Invasive Aspergillosis 9 mg/kg every 12 hours for the first 24 hours 8 mg/kg every 12 hours after the first 24 hours 9 mg/kg every 12 hours (maximum dose of 350 mg every 12 hours) Candidemia in nonneutropenics and other deep tissue Candida infections Scedosporiosis and Fusariosis Esophageal Candidiasis Not Evaluated 4 mg/kg every 12 hours 9 mg/kg every 12 hours (maximum dose of 350 mg every 12 hours) \u2022 For pediatric patients aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight use adult dosage. ( 2.4 ) \u2022 Dosage adjustment of voriconazole in pediatric patients with renal or hepatic impairment has not been established. (2.5 , 2.6 )",
    "adverseReactions_original": "\u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Voriconazole tablets are contraindicated in patients with known hypersensitivity to voriconazole or its excipients. There is no information regarding cross-sensitivity between voriconazole and other azole antifungal agents. Caution should be used when prescribing voriconazole to patients with hypersensitivity to other azoles.\n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of pimozide, quinidine or ivabradine with voriconazole is contraindicated because increased plasma concentrations of these drugs can lead to QT prolongation and rare occurrences of torsade de pointes\u00a0[see Drug Interactions (7)].\n                  \n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with sirolimus is contraindicated because voriconazole significantly increases sirolimus concentrations [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with rifampin, carbamazepine, long-acting barbiturates or St. John\u2019s Wort is contraindicated because these drugs are likely to decrease plasma voriconazole concentrations significantly [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                  \n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of standard doses of voriconazole with efavirenz doses of 400 mg every 24 hours or higher is contraindicated, because efavirenz significantly decreases plasma voriconazole concentrations in healthy subjects at these doses. Voriconazole also significantly increases efavirenz plasma concentrations [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with high-dose ritonavir (400 mg every 12 hours) is contraindicated because ritonavir (400 mg every 12 hours) significantly decreases plasma voriconazole concentrations. Coadministration of voriconazole and low-dose ritonavir (100 mg every 12 hours) should be avoided, unless an assessment of the benefit/risk to the patient justifies the use of voriconazole [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with rifabutin is contraindicated since voriconazole significantly increases rifabutin plasma concentrations and rifabutin also significantly decreases voriconazole plasma concentrations [see Drug Interactions (7) and Clinical Pharmacology (12.3)].\n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with ergot alkaloids (ergotamine and dihydroergotamine) is contraindicated because voriconazole may increase the plasma concentration of ergot alkaloids, which may lead to ergotism [see Drug Interactions (7)].\n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with naloxegol is contraindicated because voriconazole may increase plasma concentrations of naloxegol which may precipitate opioid withdrawal symptoms [see Drug Interactions (7)].\n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with tolvaptan is contraindicated because voriconazole may increase tolvaptan plasma concen Interactions trations and increase risk of adverse reactions [see Drug Interactions (7)]. \n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with venetoclax at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome [see Drug Interactions (7)].\n                  \n                  \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with lurasidone is contraindicated since it may result in significant increases in lurasidone exposure and the potential for serious adverse reactions [see Drug (7)]\n                  \n                  \n                     \u25cf\u00a0\u00a0\u00a0\u00a0\u00a0Coadministration of voriconazole with finerenone is contraindicated since it may result in significant increases in finerenone exposure and the potential for serious adverse reactions [see Drug Interactions (\n                              7\n                           )].",
    "drug": [
        {
            "name": "voriconazole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_10023"
        }
    ]
}